Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics used to end a drug program quickly.
Cullinan Therapeutics has raised $280.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2024.
Cullinan Therapeutics's investors include Adage Capital Management, Blue Owl, OrbiMed, Foresite Capital, RTW Investments.
Cullinan Therapeutics is headquartered in Cambridge, United States.
Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics used to end a drug program quickly.
Cullinan Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cullinan Therapeutics — Funding & Investors." VCBacked, April 16, 2024, https://www.vcbacked.co/company/cullinan-therapeutics. Accessed July 20, 2026.
VCBacked. (2024). Cullinan Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/cullinan-therapeutics
{{cite web |title=Cullinan Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/cullinan-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated